BioNTech (BNTX) Expected to Announce Quarterly Earnings on Monday

Key Points

• BioNTech is set to release its Q2 2025 earnings on August 4th, expecting a loss of (1.38) per share and revenues of $161.26 million.
• Analysts have mixed ratings on the stock, with a consensus price target of $136.58, while institutional ownership stands at 15.52%.
• The stock was trading at $115.31 with a market cap of $27.72 billion and a notable debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Monday, August 4th. Analysts expect BioNTech to post earnings of ($1.38) per share and revenue of $161.26 million for the quarter.

BioNTech Price Performance

BNTX stock traded down $2.34 during midday trading on Thursday, reaching $107.71. The stock had a trading volume of 506,095 shares, compared to its average volume of 950,723. The company has a market cap of $25.89 billion, a price-to-earnings ratio of -31.64 and a beta of 1.29. BioNTech has a 52-week low of $76.53 and a 52-week high of $131.49. The company has a current ratio of 10.18, a quick ratio of 10.02 and a debt-to-equity ratio of 0.01. The company's fifty day simple moving average is $107.77 and its 200 day simple moving average is $106.35.

Wall Street Analysts Forecast Growth

BNTX has been the subject of several analyst reports. Truist Financial reaffirmed a "buy" rating and set a $155.00 price objective (up from $151.00) on shares of BioNTech in a research report on Tuesday, June 3rd. Morgan Stanley lifted their target price on BioNTech from $132.00 to $133.00 and gave the company an "overweight" rating in a report on Thursday, July 10th. JPMorgan Chase & Co. decreased their target price on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a research note on Thursday, May 22nd. Citigroup reiterated a "buy" rating and set a $140.00 target price (down previously from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $138.00 price objective on shares of BioNTech in a research note on Wednesday, June 25th. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $136.58.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BioNTech stock. NewEdge Advisors LLC acquired a new stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 1,835 shares of the company's stock, valued at approximately $167,000. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.